NCT00003173View on ClinicalTrials.gov

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 1997

Primary Completion Date

May 31, 2003

Study Completion Date

May 31, 2003

Conditions
Brain and Central Nervous System TumorsChildhood Germ Cell TumorExtragonadal Germ Cell TumorOvarian CancerRetinoblastomaTesticular Germ Cell TumorUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

filgrastim

DRUG

thiotepa

PROCEDURE

autologous bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (2)

10016

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter